Retrospective Observational Study Comparing Vancomycin Versus Daptomycin as Initial Therapy for Staphylococcus aureus Infections

Clinical Therapeutics

Volumn 33, Issue 10, 2011, Pages 1391-1399

  Jobson, Synanda ^a   Moise, Pamela A ^b   Eskandarian, Romic ^a  

^a Glendale Adventist Medical Center   (United States)

^b CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

Daptomycin; Initial therapy; Staphylococcus aureus; Vancomycin

Indexed keywords

DAPTOMYCIN; VANCOMYCIN;

ABDOMINAL INFECTION; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL SKIN DISEASE; CONTROLLED STUDY; EMERGENCY CARE; FEMALE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POPULATION RESEARCH; RECURRENCE RISK; RETROSPECTIVE STUDY; SOFT TISSUE INFECTION; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; URINARY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; HOSPITAL BED CAPACITY, 300 TO 499; HOSPITALIZATION; HOSPITALS, PRIVATE; HUMANS; INJECTIONS, INTRAVENOUS; LENGTH OF STAY; MEDICAL RECORDS; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; YOUNG ADULT;

EID: 80054881149     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.09.007     Document Type: Article

References (33)

1. Howe R.A., Monk A., Wootton M., et al. Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages. Emerg Infect Dis 2004, 10:855-857.
2. Wang G., Hindler J.F., Ward K.W., et al. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006, 44:3883-3886.
3. Steinkraus G., White R., Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 2007, 60:788-794.
4. Hawkins C., Huang J., Jin N., et al. Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes. Arch Intern Med 2007, 167:1861-1867.
5. Dombrowski J.C., Winston L.G. Clinical failures of appropriately-treated methicillin resistant Staphylococcus aureus infections. J Infect 2008, 57:110-115.
6. Lodise T.P., Lomaestro B., Graves J., et al. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008, 52:1330-1336.
7. Forouzesh A., Moise P.A., Sakoulas G. Vancomycin ototoxicity: a re-evaluation in an era of increasing doses. Antimicrob Agents Chemother 2009, 53:483-486.
8. Sakoulas G., Moise-Broder P.A., Schentag J., et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004, 42:2398-2402.
9. Hidayat L.K., Hsu D.I., Quist R., et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006, 166:2138-2144.
10. Moise P.A., Sakoulas G., Forrest A., et al. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007, 51:2582-2586.
11. Lodise T.P., Graves J., Evans A., et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008, 52:3315-3320.
12. Soriano A., Marco F., Martinez J.A., et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008, 46:193-200.
13. Rybak M., Lomaestro B., Rotschafer J.C., et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009, 66:82-98.
14. Chang F.Y., Peacock J.E., Musher D.M., et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003, 82:333-339.
15. Schweitzer ML, Furuno JP, Harris AD, et al. Nafcillin or 1st generation cephalosporins (Naf/ceph1) are superior antibiotics for methicillin-susceptible S. aureus (MSSA) bacteremia. Presented at 49th Annual ICAAC Meeting; September 13, 2009; San Francisco, Calif.Paper K-522.
16. Joukhadar C., Pillai S., Wennersten C., et al. Lack of bactericidal antagonism or synergism in vitro between oxacillin and vancomycin against methicillin-susceptible strains of Staphylococcus aureus. Antimicrob Agents Chemother 2010, 54:773-777.
17. Joo J, Rogers O, Shriner K, et al. Factorspredictive oftreatmentfailure of MRSA bloodstream infections (BSIs). Presented at 49th Annual ICAAC Meeting; September 13, 2009; San Francisco, Calif.PaperK-523.
18. Carpenter C.F., Chambers H.F. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004, 38:994-1000.
19. Arbeit R.D., Maki D., Tally F.P., et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004, 38:1673-1681.
20. Fowler V.G., Boucher H.W., Corey G.R., et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006, 355:653-665.
21. Hawkins C., Huang J., Jin N., et al. Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcome. Arch Intern Med 2007, 167:1861-1867.
22. Moise-Broder P.A., Sakoulas G., Eliopoulos G.M., et al. Accessory gene regulator (agr) group II polymorphism in methicillin-resistant Staphylococcus aureus predicting failure of vancomycin therapy. Clin Infect Dis 2004, 38:1700-1705.
23. McCalla C., Smyth D.S., Robinson D.A., et al. Microbiological and genotypic analysis of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2008, 52:3441-3443.
24. Bayer A.S., Murray B.E. Initial low-dose aminoglycosides in Staphylococcus aureus bacteremia: good science, urban legend, or just plain toxic?. Clin Infect Dis 2009, 48:722-724.
25. Brouillette E., Grondin G., Shkreta L., et al. In vivo and in vitro demonstration that Staphylococcus aureus is an intracellular pathogen in the presence or absence of fibronectin-binding proteins. Microb Pathog 2003, 35:159-168.
26. Moise-Broder P.A. Practical statistics in designing research projects and evaluating the medical literature. Calif J Health Syst Pharm 2006, 18:4-15.
27. Davis S.L., McKinnon P.S., Hall L.M., et al. Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes. Pharmacotherapy 2007, 27:1611-1618.
28. Lowy F.D. Is Staphylococcus aureus an intracellular pathogen?. Trends Microbiol 2000, 8:341-343.
29. Barcia-Macay M., Lemaire S., Mingeot-Leclerq M.P., et al. Evaluation of the extracellular and intracellular activities of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006, 58:1177-1184.
30. Lemaire S., Van B.F., Mingeot-Leclercq M.P., et al. Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells. Antimicrob Agents Chemother 2007, 51:1627-1632.
31. Mortin L., Li T., Van Praagh A.D., et al. Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria. Antimicrob Agents Chemother 2007, 41:1787-1794.
32. LaPlante K.L., Rybak M.J. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004, 48:4665-4672.
33. LaPlante K.L., Woodmansee S. Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis. Antimicrob Agents Chemother 2009, 53:3880-3886.